Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (GB:0HIY)
LSE:0HIY
RESEARCH TOOLSreports
Holding GB:0HIY?
Track your performance easily
0HIY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.56 - $39.41
Previous Close$11.03
Volume847.00
Average Volume (3M)2.48K
Market Cap
$65.66M
Enterprise Value$33.72M
Total Cash (Recent Filing)$67.19M
Total Debt (Recent Filing)$35.24M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 03, 2025EPS Estimate
-$1.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.66
Shares Outstanding5,759,750
10 Day Avg. Volume1,415
30 Day Avg. Volume2,483
Standard Deviation0.23
R-Squared0.11
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.75
Price to Sales (P/S)0.65
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.34
Enterprise Value/Gross Profit-107.72
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$18.67Price Target Upside69.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Atara Biotherapeutics News
PremiumCompany Announcements
Atara Biotherapeutics Reports Q3 2024 Financial Progress
PremiumCompany Announcements
Atara Biotherapeutics Advances with Strategic Partnerships
PremiumCompany Announcements
Atara Biotherapeutics Appoints Eric Hyllengren as COO
Options Prices
Currently, No data available
---
Ownership Overview
33.52% Insiders
7.43% Mutual Funds
20.40% Other Institutional Investors
35.43% Public Companies and
Individual Investors
0HIY FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest share price was $6.56 and its highest was $39.41 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Currently, no data Available
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 71 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Nov 12, 2024. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$1.888 by -$1.042.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -$1.86.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 5,759,750 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$2.93 in its last earnings report, missing expectations of -$1.888. Following the earnings report the stock price went up 19.52%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Among the largest hedge funds holding Atara Biotherapeutics’s share is Woodline Partners LP. It holds Atara Biotherapeutics’s shares valued at N/A.
---
Atara Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.67 (69.34% Upside)
$18.67 (69.34% Upside)
Insider Transactions
Sold Shares
Worth $45.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.41%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
---
0HIY Earnings Call
Q3 2023
0:00 / 0:00
---
0HIY Stock 12 Month Forecast
Average Price Target
$18.67
▲(69.34% Upside)
Technical Analysis
Atara Biotherapeutics
―
Allogene Therapeutics
―
Fate Therapeutics
―
Cellectis SA
―
Gritstone bio
―
Best Analysts Covering 0HIY
1 Year
1 Year Success Rate
17/40 ratings generated profit
1 Year Average Return
+1.23%
reiterated a buy rating last month
Copying John Newman's trades and holding each position for 1 Year would result in 42.50% of your transactions generating a profit, with an average return of +1.23% per trade.
---